Flonoltinib maleate

马来酸氟诺替尼

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameFlonoltinib maleate
Drug Alias NameFlunotinib maleate氟诺替尼Flonoltinib
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitorsCyclin-dependent kinase 6 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase receptor FLT3Cyclin-dependent kinase 6
Therapy Area/IndicationsGraft vs Host DiseaseAlopecia AreataLymphohistiocytosis, Hemophagocytic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesChengdu Zenitar Biomedical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChengdu Zenitar Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseLymphohistiocytosis, HemophagocyticPrimary Myelofibrosis +[8] 
Inactive IndicationsAlopecia Areata

Other Information

ATC CodeL01XE
Related LinksN/A